Glycogen synthase is activated by protein phosphatase type-i (PP-1). The spontaneous PP-1 activity accounts for only a small fraction of total PP-1 activity, which can be exposed by trypsin digestion of inhibitor proteins in the presence of Mn2+. We determined total PP-1 activity in muscle biopsies from insulin-sensitive and -resistant nondiabetic Pima Indians. Inhibitor-2 sensitive PP-1 represented 90% oftotal phosphatase activity. Spontaneous and total PP-1 activities were reduced in insulin resistant subjects (P < 0.05-0.01), suggesting that the reduced PP-1 activity is not the result of inhibition by trypsinlabile phosphatase regulatory subunits. This difference was further investigated by Western blots using two different antibodies. An antibody raised against the rabbit muscle PP-I catalytic subunit was used to analyze muscle extracts concentrated by DEAE-Sepharose adsorption. An antibody raised against a peptide derived from the COOH-terminal end ofthe PP-1 catalytic subunit was used to analyze crude muscle extracts. Both antibodies recognized a PP-1 catalytic subunit of -33 kD, which unexpectedly was more abundant in insulin-resistant subjects (P < 0.05-0.01). The increase in the tissue PP-1 protein content may be a response to compensate for the impairment in the enzyme activity. (J. Clin. Invest. 1991Invest. . 88:1540Invest. -1545
Introduction
We have previously shown a close relationship between in vivo insulin-mediated glucose disposal rate and insulin-stimulated glycogen synthase activity of skeletal muscle in man and suggested that a defect in the regulation of this enzyme by insulin may contribute to insulin resistance in Pima Indians (1) . Although the mechanisms for insulin regulation of glycogen synthase are not fully understood, changes in the phosphorylation state of this enzyme alter its activity (2, 3) and it has been proposed that activation of this enzyme by insulin may be achieved through inhibition ofprotein kinases known to phosphorylate glycogen synthase or by stimulation ofprotein phosphatases, which dephosphorylate this enzyme (2) (3) (4) (5) (6) .
Alemany et al. (7) have suggested that in vivo dephosphorylation ofboth glycogen synthase and phosphorylase are primarily catalyzed by the catalytic subunit of protein phosphatase type-I (PP-i).1 This enzyme has both active and inactive forms bound to targeting regulatory subunits distributed in different cell compartments (8) (9) (10) . Skeletal muscle glycogen synthase phosphatase activity is reduced in insulin-resistant subjects, both fasting (11, 12) and during in vivo insulin stimulation (12) , but it is not known whether this is due to an abnormality in the catalytic subunit of PP-I or due to inhibition by regulatory subunits. The present study was undertaken to investigate whether the total activity of PP-I (independent of inhibitor proteins) is impaired and if the total enzyme protein content is deficient in insulin-resistant man. The results show a reduction in total PP-I activity, but an increase in the immunoreactive PP-1 catalytic subunit in association with insulin resistance.
Methods
Subjects. 12 Pima Indians were studied. They gave informed consent, and the studies were approved by the ethics committees ofthe National Institutes of Health, the Indian Health Service, and the Gila River Indian Community, where the subjects were living. Fitness for the study was determined by medical history, physical examination, electrocardiography, and routine biochemical, hematological, and urine testing. None ofthe subjects was taking any medication and no subject had any abnormalities on these examinations. They were studied at the Clinical Diabetes and Nutrition Section of the National Institutes of Health, Phoenix, AZ, after being stabilized for -7 d on a weight-maintaining diet (20% protein, 50% carbohydrate, and 30% fat). Body fat was determined by underwater weighing, with simultaneous determination of residual lung volume, and fat-free mass (FFM) was calculated. Diabetes was excluded after an oral glucose tolerance test using World Health Organization Criteria.
Subjects were further characterized by their glucose disposal rate during a euglycemic clamp, performed as previously described in detail (13) . In brief, the plasma insulin concentration was raised by means of a primed continuous infusion of insulin, and glucose was infused to maintain the plasma glucose at the basal level. The rate of glucose uptake is a measure ofinsulin action. Two infusions ofinsulin (Velosulin; Nordisk, Bethesda, MD) were given consecutively, each lasting 100 min: 40 mU/m2.* min (low dose) and 400 mU/M2* min (high dose), resulting in steady-state plasma insulin concentrations of 132±12 mU/ liter and 2442±161 mU/liter. Before and during the infusion ofthe low dose of insulin, tracer amounts of [3-3H] glucose were infused to mea-sure the rate of appearance ofglucose. Endogenous glucose production was calculated by subtracting the rate of exogenous glucose infusion from the total rate of appearance of glucose calculated using Steele's non-steady state equations (14) . The total glucose disposal rate at low insulin dose is equal to the total rate of glucose appearance. Subjects were arbitrarily considered insulin resistant if their glucose disposal rates at the low and high doses of insulin were < 3 and 9 mg/kg FFM per min, respectively, whereas they were considered insulin sensitive if their glucose disposal rates were higher. The characteristics of the subjects are shown in Table I .
Muscle extracts. After an overnight fast, percutaneous muscle biopsies were taken from the quadriceps femoris muscle after local anesthesia of skin and fascia with xylocaine. Specimens (-300 mg) were collected within 5 min using the Bergstrom needle (Depuy, Phoenix, AZ), and were frozen in liquid nitrogen within 15 s, lyophilized, and powdered (12) . Muscle powder was stored at -70'C until assayed. Frozen muscle powder was homogenized using an Omni homogenizer (Omni International, Waterbury, CT) in 15 Mi/mg powder of an ice-cold 20 mM Mops buffer, pH 7.5, containing 5 mM EDTA, 0.5 mM EGTA, 5 mM NaN3, 1 mM DTT, and 0.15 mM or 0.3 mM of freshly added PMSF (buffer A). The homogenates were centrifuged at 10,000 gfor 20 min at 4VC in a Sorvall centrifuge. The resulting supernatant was used forthe assay ofphosphorylase phosphatase. Alternatively, homogenization was performed in 30 Ml/mg powder of 20 mM Mops buffer, pH 7.5, containing 10 mM EDTA, 10 mM EGTA, 10 mM benzamidine, 0.3% ,B-mercaptoethanol, 5 jg/ml leupeptin, 1 ug/ml pepstatin, 1 mM DTT, and 0.1 mM of freshly added PMSF (buffer B). After centrifugation, the supernatant was used for immunological detection of PP-1.
Phosphorylase phosphatase assay. Phosphorylase phosphatase activity was assayed by the release of 32p from [32P]-phosphorylase a as described by Nimmo and Cohen (15) . Rabbit muscle phosphorylase b (P-6635; Sigma Chemical Co., St. Louis, MO) was phosphorylated with phosphorylase kinase (P-2014, Sigma Chemical Co.) and [gamma-32P]-ATP (sp act 50-80 cpm/pmol; New England Nuclear, Boston, MA) as described by Antoniw et al. (16) . Muscle extracts and [32P]-phosphorylase a (2 mg/ml) were mixed in a total volume of 70 M1 and the mixture was incubated at 30°C for 5 min. The reaction was terminated by adding 100 Ml of ice-cold 17.5% TCA and 100 ,l of 6 mg/ml BSA. Denatured protein was removed by centrifugation at 10,000 g for 4 min at 4°C, and the amount of radioactivity was determined in 200 M1 of the supernatant. The radioactivity in the absence of muscle extract (nonspecific dephosphorylation of phosphorylase a) was subtracted from the activity in the presence of muscle extract. Phosphatase activity was expressed as nanomoles 32P hydrolyzed per gram dry weight muscle per minute (nanomoles 32p/g. min). As assayed, the enzyme activity reflects the spontaneous, physiologic phosphatase activity. PP-1 has been found in active or inactive conformations (9, 10, 17) , in association with heat-stable inhibitors or anchored to glycogen, microsomes, and myofibrils by targeting proteins (8) . These heat-stable inhibitors and targeting proteins may be destroyed by mild proteolysis to expose the latent enzyme activity. Inactive PP-I can be activated by (19, 20) . Briefly, eluates were boiled in Laemmli sample buffer for 5 min and the mixtures were resolved by SDS/10% PAGE in slab gels. Molecular weights were estimated using prestained molecular weight standards (Bio-Rad Laboratories, Inc., Richmond, CA) which had been recalibrated with Bio-Rad's unstained standards. Proteins were electrically transferred from the gels onto nitrocellulose membranes using a Bio-Rad apparatus at 30 V overnight followed by 60 V for 60 min. After protein transfer, the nitrocellulose was blocked for 60 min with a quench solution (10 mM Tris-HCl, 150 mM NaCl, 5% BSA, pH 7.4). The nitrocellulose was incubated overnight at room temperature with specific, affinity-purified sheep anti-PP-I catalytic subunit IgGs (19, 20) . The bound IgGs were reacted for 2 h at room temperature with rabbit anti-sheep IgGs which in turn were detected after 1251-protein A binding for 60 min. The nitrocellulose was used to expose Kodak X-omat AR x-ray film at -70°C with a DuPont Cronex intensifying screen (Eastman Kodak Co., Rochester, NY). Autoradiographic bands were quantified by densitometry using the BioRad video densitometer or the model GS300 scanning densitometer (Hoefer Scientific Instruments, San Francisco, CA) connected to a model 3390A integrator (Hewlett-Packard Co., Avondale, PA).
Crude muscle extracts in buffer B were submitted to SDS/PAGE and Western immunoblotting as described above with the following exceptions. The first antibody was prepared against a peptide (Cys-ThrPro-Pro-Arg-Asn-Ser-Ala-Lys-Ala-Lys-Lys) corresponding to the COOH-terminus ofPP-I catalytic subunit. The peptide was coupled to the carrier protein keyhole limpet hemocyanin through the cysteine residue added to the NH2-terminus, the antibodies were raised against the coupled peptide in rabbits and immunopurified using the peptide covalently bound to Immobilon AV membrane (Millipore Corp., Bedford, MA). The purified antibody was specific for PP-I catalytic subunit (21) . The IgGs were detected by 1251-protein A binding. After autoradiography, the immunoreactive bands were cut out and the incorporated radioactivity was determined in a gamma-counter.
Other assays. Protein content ofmuscle extracts was determined by the Bio-Rad protein dye assay. Plasma glucose concentration was measured by the glucose oxidase method using a glucose analyzer (Beckman Instruments, Inc., Fullerton, CA). Plasma insulin concentrations were determined by RIA (22) .
Statistical analyses. Analyses were performed using Statistical Analysis System Institute computer software (Cary, NC). The unpaired, two-tailed t-test was used to calculate the statistical significance of the differences. Data are presented as means+SEM, unless otherwise indicated.
Results
Phosphorylase phosphatase activity. Phosphatase activity in muscle extracts from experimental groups was determined at the same time as in a muscle powder pool from four different subjects, used as a standard. The coefficient ofvariation ofthis pooled sample was 16% for the assay of spontaneous phosphatase activity and 12% for total (post-trypsin/Mn2) phosphatase activity (Table II) . Muscle protein content was similar between resistant (310±20 mg/g dry wt) and sensitive (347±40 mg/d dry wt) subjects. The intergroup differences in phosphatase activities were determined in two sets of experiments. In both experiments, spontaneous and total activities were significantly reduced in insulin-resistant subjects (Table III) .
To study the contribution of PP-l to the observed activity, trypsin/Mn2+-treated extracts were incubated with inhibitor-2. Under these conditions, which define PP-1, phosphatase activity was inhibited by -90% (Tables II and III A) . The remaining activity, which is an estimate of phosphatase 2A activity, was not different among the groups. The individual effects of Mn2' and trypsin were also studied (Table III B ). Mn2' alone increased phosphatase activity by -40% in insulin-sensitive and by -60% in -resistant subjects to give about the same level of activity in the two groups. An approximate threefold increase in phosphatase activity was observed in both groups in the presence of trypsin alone. When Mn2' and trypsin were combined, the highest level of phosphatase activity (total) was obtained, with an increase of 4.5-fold in sensitive and of 4.9-fold in resistant subjects, compared to the spontaneous activity. Like spontaneous and total phosphatase activities, posttrypsin activity was significantly lower in insulin-resistant than in sensitive subjects (Table III B) .
Western immunoblotting ofprotein phosphatase type-l. We investigated whether the reduced activity of phosphatase in insulin-resistant subjects is due to a reduced content ofPP-l catalytic subunit. Muscle extracts were immunoblotted with a sheep antibody developed against the rabbit muscle PP-l catalytic fragment (19, 20) . This antibody requires 100-500 ng PP-1 for detection and did expose a -33-kD band in crude muscle extracts analyzed by Western blotting. However, the intensity of staining was weak and not readily detected over a range ofdilutions. Therefore, instead ofcrude tissue extracts, DEAESepharose concentrates of muscle extracts were used in Western blotting, exposing the major band of -33 kD (see Fig. 1 ).
The antibody also recognized a band of -70 kD and two faint bands of -37 and -45 kD but these were not consistently present in all the samples and were therefore excluded from comparative studies. In two preliminary experiments, PP-1 im- Fig. 1 is an autoradiogram of a series of diluted samples comparing an insulin-resistant and an insulin-sensitive subject, showing increased PP-I immunoreactivity in the resistant subject.
To quantify PP-I immunoreactivity, four serial dilutions of rabbit muscle PP-I used as a standard were analyzed in each experiment in parallel with four dilutions of muscle DEAE extracts from one sensitive and one resistant subject. For every subject a PP-1 concentration index was calculated as the ratio of the slope ofthe OD vs. sample protein for this subject to the slope of the O.D. vs. protein for the rabbit PP-l (defined as 100). As shown in Table IV protein for this subject to the slope ofthe OD vs. protein for the rabbit PP-I used as a standard (defined as 100). This PP-I concentration index (mean±SEM) is shown, and the number of subjects is shown in parentheses. Anti-peptide antibody. Crude muscle extracts were immunostained with a rabbit antibody against a synthetic peptide derived from the COOH-terminal end of the PP-I catalytic subunit.
PP-I was quantitated by '25I-protein A assay as described in Methods.
The autoradiograph corresponding to these data is illustrated in Fig.  2 . Data are shown as mean counts per minute bound (±SEM), and the number ofsubjects is shown in parentheses. * P < 0.01 vs. sensitive. $ P < 0.05 vs. sensitive.
thetic peptide representing the COOH-terminal end ofthe PP-1 catalytic subunit. PP-I was quantitated by '25I-protein A assay as described in Methods. This antibody like the anti-PP-I catalytic fragment, detected a major band ofimmunoreactivity of -33 kD (Fig. 2) the intensity of which increased with decreasing in vivo insulin-mediated glucose disposal rate. The immunoreactivity bound to the 33-kD band was significantly higher in the resistant compared to the sensitive subjects (Table  IV) . Similar results were obtained when the autoradiography bands were quantitated by densitometry (not shown). Other bands were evident at -45 and -37 kD. However, there was no difference in the immunoreactivity of the 45-kD band between sensitive (1,605±230 cpm bound) and resistant (1,654±176 cpm bound) subjects, and the 37 kD was too faint kD 35-30- a b c d e f M 6 6.5 7.9 9 9 9.9 11.7 9.2 Figure 2 . Autoradiograph of PP-I in crude muscle extracts. Muscle extracts from seven subjects were subjected to electrophoresis and electroblotting, and were immunoblotted using affinity purified IgGs raised against the 10 amino acid COOH-terminal peptide ofthe rabbit muscle catalytic subunit of PP-i (see Methods). Quantitation of PP-I with this anti-peptide antibody is shown in Table IV comparing insulin-sensitive and -resistant subjects. The material loaded per lane was equivalent to 1 mg dry wt muscle. The glucose disposal rates at the high dose of insulin are shown for the different subjects (a-g).
to be included in comparative studies. Results with the two anti-PP-I antibodies used in this study support the conclusion that muscle content of PP-I catalytic subunit is increased in insulin-resistant subjects.
Discussion
Basal and insulin-stimulated activities of glycogen synthase phosphatase are reduced in insulin-resistant Pima Indians (11, 12). We have investigated the nature ofthe defect and found a significantly reduced spontaneous activity of phosphorylase phosphatase and lower total PP-I activity in insulin-resistant subjects.
Protein phosphatases involved in the regulation ofglycogen metabolism have been classified into type-l and type-2 (5) according to their specificity for the subunits of the substrate phosphorylase kinase and their inhibition by heat stable inhibitor proteins (inhibitor-I and inhibitor-2). PP-I comprises a catalytic subunit bound to targeting subunits such as the G-subunit in glycogen particles and in the microsomes (8) . It is now known that PP-I catalytic subunit exists in an active but inhibited conformation in the microsomes (10) , whereas in the cytosol the PP-I catalytic subunit complexed with inhibitor-2 may be mostly inactive (23) . The catalytic subunit in the glycogen particles is considered to exist only in an active conformation (24) . It appears therefore that spontaneous phosphatase activity is mostly PP-I in glycogen particles, whereas after trypsin digestion phosphatase activity is the result of the release of active PP-I from glycogen and microsomal particles as well as from inhibitor-2. The PP-I that is in an inactive conformation may be further activated by Mn2+ or Co2+ treatment, so the combination of any of these divalent cations with trypsin allows the measurement of total PP-1 activity in tissue extracts (4, 10, 17, 18) .
The decrease in the spontaneous phosphatase activity in insulin-resistant subjects indicates that active PP-1 is reduced in the cytosol, glycogen particles, or both. This activity increased towards normal after Mn2+ treatment, suggesting that the Mn2' responsive form ofPP-1 (4, 25) might be abnormally high in insulin-resistant subjects. Whether the PP-I defect is primary or secondary to hormonal dysregulation is not known.
The hormonal regulation of PP-I activity is still poorly understood. Heat-stable inhibitors and targeting subunits have been shown to have a regulatory function on PP-I activity. From studies on experimental diabetes it is not clear whether changes in heat-stable inhibitor activity determine the decreased PP-I activity associated with insulin deficiency (26) (27) (28) . The G-subunit is thought to be a specific receptor for PP-I (10) and is a physiological substrate for cAMP-dependent protein kinase. Phosphorylation of the G-subunit in response to adrenaline triggers the release of the catalytic subunit into the cytosol, but this has no apparent direct effect on PP-I activity (8) . Dissociation ofthe catalytic subunit ofPP-I from glycogen has also been observed in the presence ofinhibitor-2 (29) . This dissociation of PP-I from the G-subunit has been proposed as an inactivation mechanism for PP-1, because in animals adrenaline decreases the PP-I activity associated with glycogen particles (30) . Also, in a recent study, insulin stimulated a protein kinase that activated glycogen-bound PP-I by a mechanism that did not involve dissociation, but rather G-subunit phosphorylation on a specific site, also phosphorylated by cAMPdependent protein kinase in response to adrenaline (31) .
Theoretically, regulatory or targeting proteins could account for the impaired PP-1 activity in insulin-resistant subjects, either by a limited response to insulin or by an excessive response to counterregulatory hormones. The lower activity of PP-l observed in insulin-resistant subjects is not likely due to regulatory proteins because the abnormality is not corrected by trypsin. Trypsin also removes a 4-kD peptide (32, 33) at the COOH-terminal end of the catalytic subunit, leaving a slightly more active, stable, nicked catalytic subunit. The low total PP-1 activity observed in insulin-resistant subjects is not an artifact introduced by trypsin because PP-l activity was also low before trypsin treatment. The defect resides in the PP-l catalytic subunit, because inhibitor-2 removed the activity difference between insulin-sensitive and -resistant subjects. Inhibitor-2-sensitive phosphatase was -90% of total phosphatase activity, similar to that reported for the rabbit (9, 34), indicating that virtually all the phosphatase activity in human muscle was due to PP-1. Similar results were obtained using okadaic acid to inhibit PP-1 (unpublished observations).
A significant reduction in the total PP-1 activity in insulinresistant subjects could be simply explained by a reduced level of PP-I catalytic subunit. Antibodies specific for rabbit muscle PP-1 catalytic subunit could be used to determine the content of human muscle PP-1 catalytic subunit because the amino acid sequence of PP-l catalytic subunit is highly conserved (35) , and has been predicted by gene sequence analysis to be identical in humans and the rabbit (36) . We first used an antibody raised against the PP-l catalytic fragment on muscle extracts concentrated by ion-exchange adsorption (19, 20 (8, 37, 38) . This is the first time an immunologic determination of PP-1 or enzymatic determination of total PP-I activity has been performed in a study of human insulin resistance. There was a dissociation between PP-l protein level and total enzymatic activity in these subjects. A similar dissociation was recently reported by Gruppuso and Brautigan (39) who found that immunoreactive PP-I in fetal rat liver had a reduced response to metabolic and hormonal changes.
It is not known at this time whether the PP-I defect is due to genetic or posttranslational alterations in the catalytic subunit, and there is no evidence for direct covalent regulation of this subunit by insulin. The only documented posttranslational modification of this subunit is its phosphorylation on tyrosine by the oncogene product pp60V_= which abolishes the enzyme activity (40) .
The complex regulation of glycogen synthase involves activation by PP-I and inhibition by various kinases as previously discussed (41) . We have recently reported an increased cAMPdependent protein kinase activity in insulin resistant subjects (41) . The relative importance ofthis abnormal kinase and PP-l activities to the reduction ofglycogen synthase activity and the pathogenesis of insulin resistance remains unknown. Recent studies (42, 43) also show that PP-l may be involved in the regulation of glucose transport, indicating a multisite action of this enzyme on glucose metabolism. This complexity ofactions and regulation makes it difficult to quantitatively predict what decrements of insulin-mediated glucose disposal would result from given decrements of PP-l activity. This issue is further complicated by the fact that measured PP-1 activity and stimulation by insulin change with the concentration ofthe enzyme (unpublished observations). Under the conditions of the present study, however, it is clear that a decrease of PP-l activity was associated with in vivo insulin resistance in man.
In summary, we show that total PP-I activity is decreased whereas the level of PP-l catalytic subunit is increased in subjects with insulin resistance. This reduced PP-I activity appears to be due to a defect in the catalytic subunit itself and not interaction with heat-stable inhibitors or regulatory proteins.
